Healios is engaged in the development of cellular and tissue-based products, which are expected to be novel therapies for various diseases. We will simultaneously encourage work in expanding our small molecule compound drug technology BBG250.
Below are the product pipelines we are currently working on.
Development of an ophthalmic surgery stain using BBG250 as a major component (already available in Europe as a CE Mark product).
Please refer to the page Development of Treatments for Age-Related Macular Degeneration (AMD) involving transplantation of iPS cell-derived retinal pigment epithelial (RPE) cells as an iPSC regenerative medicine.
Please refer to the page Development of Organ Anlage Transplantation Therapy involving a technology to create functional human organs using pluripotent stem cells (such as iPS cells).
Development of regenerative medicine using MultiStem for ischemic stroke.